Immunity and Hepatitis C: A Review

被引：0
作者：
Rebecca R. Terilli
Andrea L. Cox
机构：
[1] Johns Hopkins University School of Medicine,Division of Infectious Diseases
来源：
Current HIV/AIDS Reports | 2013年 / 10卷
关键词：
Hepatitis C; HCV; Viral hepatitis; Hepatitis; Immunity; Innate immune response; Interferons; IFN; Cellular immunity; Adaptive immune response; Neutralizing antibodies; Chronic infection; Acute infection; Liver disease; Spontaneous clearance; Treatment response; SVR; Vaccination; HIV; HIV-HCV coinfection; Coinfection; T cell response; B cell response; Interleukin 18; Interleukin 28B; Virus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatocellular carcinoma worldwide. Due to shared transmission routes, the prevalence of HCV is especially high among individuals infected with HIV. HIV uninfected individuals spontaneously clear HCV approximately 30 % of the time, while the rate of control in HIV infected individuals who subsequently acquire HCV is substantially lower. In addition, complications of HCV are more frequent in those with HIV infection, making liver disease the leading cause of non-AIDS-related death in HIV infected individuals. This review summarizes recent advances in understanding the role of the innate and adaptive immune responses to HCV in those with and without HIV. Further defining the interaction between hepatitis C and the host immune system will potentially reveal insights into HCV pathogenesis and the host’s ability to prevent persistent infection, as well as direct the development of vaccines.
引用
收藏
页码：51 / 58
页数：7
相关论文
共 217 条
  • [1] Thomas DL(2009)Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 798-801
  • [2] Thio CL(2009)Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence J Clin Invest 119 1745-1754
  • [3] Martin MP(2002)Hepatitis C prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group Clin Infect Dis 34 831-7
  • [4] Rehermann B(2001)Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection Clin Infect Dis 32 492-497
  • [5] Sherman KE(2005)Evasion of intracellular host defense by hepatitis C virus Nature 436 939-45
  • [6] Rouster SD(2005)Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of Toll-like receptor 3 adaptor protein TRIF Proc Natl Acad Sci USA 102 2992-7
  • [7] Chung R(2012)IL28B and the control of hepatitis C virus infection Gastroenterology 139 1865-1876
  • [8] Bica I(2009)Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399-401
  • [9] McGovern B(2009)Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105-1109
  • [10] Dhar R(2009)IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 1100-1104
12345678910